Iatrogenic Creutzfeldt-Jakob Disease (iCJD)

Iatrogenic Creutzfeldt-Jakob Disease (iCJD)

Overview

Iatrogenic Creutzfeldt-Jakob Disease (iCJD) is a rare form of CJD transmitted through accidental exposure to prion-contaminated biological materials or medical devices. It represents the first demonstrated example of医源性 (iatrogenic) transmission of a prion disease in humans and has significantly influenced medical safety protocols for tissue banking, surgery, and blood product handling. iCJD accounts for approximately 1-2% of all CJD cases worldwide. [@human]

Historical Context

First Recognized Cases

The first recognized cases of iCJD were reported in 1974, resulting from corneal transplantation from an infected donor [1]. Subsequently, additional cases have been linked to: [@iatrogenic]

• Dura mater grafts (1970s-1980s): Largest single source of iCJD
• Human growth hormone (1959-1985): Contaminated pituitary extracts
• Human pituitary gonadotropin (1960s-1970s)
• Blood products (rare, debated)
• Neurosurgical instruments (extremely rare)

Impact on Medical Practice

The recognition of iCJD has led to: [@creutzfeldtjakob2024]

• Stringent decontamination protocols for surgical instruments
• Donor screening policies for tissue and organ transplantation
• Blood donor deferral policies
• Development of prion-resistant medical devices [2]

Epidemiology

Case Distribution by Exposure Type

...

Iatrogenic Creutzfeldt-Jakob Disease (iCJD)

Overview

Iatrogenic Creutzfeldt-Jakob Disease (iCJD) is a rare form of CJD transmitted through accidental exposure to prion-contaminated biological materials or medical devices. It represents the first demonstrated example of医源性 (iatrogenic) transmission of a prion disease in humans and has significantly influenced medical safety protocols for tissue banking, surgery, and blood product handling. iCJD accounts for approximately 1-2% of all CJD cases worldwide. [@human]

Historical Context

First Recognized Cases

The first recognized cases of iCJD were reported in 1974, resulting from corneal transplantation from an infected donor [1]. Subsequently, additional cases have been linked to: [@iatrogenic]

• Dura mater grafts (1970s-1980s): Largest single source of iCJD
• Human growth hormone (1959-1985): Contaminated pituitary extracts
• Human pituitary gonadotropin (1960s-1970s)
• Blood products (rare, debated)
• Neurosurgical instruments (extremely rare)

Impact on Medical Practice

The recognition of iCJD has led to: [@creutzfeldtjakob2024]

• Stringent decontamination protocols for surgical instruments
• Donor screening policies for tissue and organ transplantation
• Blood donor deferral policies
• Development of prion-resistant medical devices [2]

Epidemiology

Case Distribution by Exposure Type

| Exposure Type | Reported Cases | Risk Level | [@first]
|--------------|----------------|-----------| [@selecting]
| Dura mater graft | ~200+ | Highest | [^6]
| Human growth hormone | ~229 | High | [^7]
| Corneal transplant | 3 | Low | [^8]
| Neurosurgery | 4 | Very low | [^9]
| Blood transfusion | 5 (possible) | Very low |

Geographic Distribution

• Japan: Highest number (dura mater grafts)
• France: Second highest
• United States: Significant number
• United Kingdom: Cases linked to growth hormone
• Other countries: Sporadic cases

Incubation Periods

Incubation periods vary significantly by exposure type:

• Dura mater graft: 1.5-25 years (median ~12 years)
• Human growth hormone: 5-30 years (median ~12 years)
• Corneal transplant: 1.5-5 years
• Neurosurgery: 1-7 years
• Blood transfusion: 5-8 years (possible cases)

Age at Onset

• Growth hormone cases: Mean age ~32 years (younger at exposure)
• Dura mater cases: Mean age ~55 years
• Overall: Variable, depends on exposure age [3]

Pathophysiology

Transmission Routes

Direct CNS exposure: Dura mater grafts, corneal transplants, neurosurgery

Peripheral exposure: Growth hormone injections, blood products

Neuroinvasion: Prions transported to CNS via peripheral nerves

Dose-Response Relationship

• Higher inoculum → shorter incubation period
• Direct CNS exposure → shorter incubation than peripheral
• Species barrier → affects transmission efficiency

Neuropathology

iCJD shows similar neuropathological features to sporadic CJD:

• Spongiform change: Vacuolation of neuropil
• Neuronal loss: Progressive neuronal degeneration
• Prion deposition: PrP^Sc in various patterns
• Astrocytic gliosis: Reactive [astrocytes](/entities/astrocytes)
• Amyloid plaques: Variable, may be absent

Prion Strain Characteristics

• Maintains the strain characteristics of the donor's prion
• Preserves the molecular fingerprint (glycosylation pattern)
• Similar to sporadic CJD in most cases [4]

Clinical Presentation

Typical Clinical Features

Cognitive symptoms:

• Progressive cognitive decline
• Memory impairment
• Executive dysfunction
• Dementia (typically rapidly progressive)

Neurological symptoms:

• Ataxia (cerebellar involvement common)
• Myoclonus (often early and prominent)
• Pyramidal signs
• Extrapyramidal signs
• Visual disturbances
• Dysarthria

Psychiatric symptoms:

• Depression
• Anxiety
• Behavioral changes
• Psychosis (less common)

Clinical Variability

• Growth hormone cases: Often present with cerebellar ataxia early
• Dura mater cases: Variable presentation, often typical CJD
• Blood transmission: Variable, limited cases

Disease Progression

• Rapid decline: Typically faster than sporadic CJD
• Myoclonus: Often early and prominent
• Akinetic mutism: Common in late stages
• Survival: Usually 4-12 months from symptom onset [5]

Diagnosis

Clinical Criteria

Possible iCJD:

• Progressive dementia
• Plus at least two of: myoclonus, visual/cerebellar symptoms, pyramidal/extrapyramidal signs
• History of recognized iatrogenic exposure

Probable iCJD:

• Above clinical criteria
• Plus characteristic EEG (periodic sharp wave complexes)
• Plus characteristic MRI findings

Definite iCJD:

• Neuropathological confirmation
• OR positive prion detection plus documented exposure

Diagnostic Tests

Neuroimaging:

• MRI brain: Cortical ribboning, basal ganglia hyperintensity
• Diffusion-weighted imaging: Restricted diffusion
• May be indistinguishable from sporadic CJD

EEG:

• Periodic sharp wave complexes in ~60% of cases
• May be absent early in disease

CSF analysis:

• 14-3-3 protein: Positive in most cases
• Total [tau](/proteins/tau): Elevated
• Neuronal markers

Genetic testing:

• PRNP sequencing to exclude familial CJD
• Codon 129 genotyping

Post-mortem:

• Definitive diagnosis
• Neuropathological confirmation
• PrP immunohistochemistry [6]

Differential Diagnosis

• Sporadic CJD
• Familial CJD
• Variant CJD
• Other rapidly progressive dementias
• Autoimmune encephalitis
• Paraneoplastic encephalitis
• Viral encephalitis
• Metabolic encephalopathies

Prevention and Safety Measures

Historical Precautions (Post-iCJD Recognition)

Dura mater:

• Lyophilized dura replaced with synthetic alternatives
• Donor screening implemented
• Heat treatment of dura grafts

Growth hormone:

• Recombinant human growth hormone replaced pituitary-derived
• Screening of pituitary donors

Surgical instruments:

• Extended sterilization protocols (1N NaOH, autoclaving)
• Dedicated instrument sets for high-risk procedures
• Single-use instruments where possible

Blood products:

• Donor deferral for CJD risk factors
• Leukodefiltration
• Plasma products: Heat treatment

Current Safety Protocols

WHO Guidelines:

• Decontamination: 1N NaOH for 1 hour, or 2% available chlorine
• Autoclaving: 134°C for 18 minutes (prevacuum)
• Single-use preference for high-risk procedures

National Policies:

• Vary by country
• US: FDA guidance on CJD
• EU: Medical device regulations
• Japan: Stringent tissue screening [7]

Treatment

Disease-Modifying Therapy

No disease-modifying treatments are available. Investigational approaches:

• Quinacrine (not effective)
• Pentosan polysulfate (not effective)
• Anti-prion antibodies (experimental)
• Gene therapy approaches (investigational)

Symptomatic Management

Motor symptoms:

• Myoclonus: Clonazepam, valproic acid, levetiracetam
• Ataxia: Physical therapy, assistive devices
• Spasticity: Baclofen, tizanidine

Cognitive symptoms:

• Supportive care
• Environmental modifications
• Caregiver education

Psychiatric symptoms:

• Antidepressants (SSRIs)
• Antipsychotics for behavioral disturbances

General care:

• Nutritional support
• Swallowing assessment
• Pulmonary hygiene
• Pressure ulcer prevention [8]

Prognosis

• Median survival: 4-12 months from symptom onset
• Incubation period: 1-30 years (exposure-dependent)
• Age at onset: Variable (30-70 years)
• Outcome: Uniformly fatal
• Predictors: Age at onset, codon 129 genotype, exposure type

Public Health Implications

Surveillance

• Mandatory reporting of suspected iCJD
• International surveillance networks
• Investigation of each suspected case
• Tracking of exposure sources

Risk Assessment

• Estimated risk from blood products: Very low (~1 in 2-3 million)
• Risk from surgical instruments: Extremely low with proper decontamination
• Risk from tissue transplantation: Mitigated by screening

Future Concerns

• Long incubation periods may lead to additional cases
• Subclinical carriers possible
• Need for continued vigilance
• Development of sensitive detection methods [9]

Conclusion

Iatrogenic CJD represents a significant chapter in the history of prion disease research, demonstrating that human prion diseases can be transmitted through medical procedures. While rare, iCJD has profoundly influenced medical safety practices and continues to inform policies around tissue banking, surgical instrument decontamination, and blood product safety. The prevention of iCJD through stringent safety protocols remains a model for addressing emerging infectious risks in medicine.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Human Prion Disease: Pathogenesis, Diagnosis and Public Health.](https://pubmed.ncbi.nlm.nih.gov/41754559/) (2026 Feb 6) - Viruses
• [Iatrogenic cerebral amyloid angiopathy: more cases to come.](https://pubmed.ncbi.nlm.nih.gov/41473224/) (2025) - Frontiers in neurology
• [Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2024.](https://pubmed.ncbi.nlm.nih.gov/41118651/) (2025 Oct 22) - Communicable diseases intelligence (2018)
• [First Endoscopic Transplantation of a Tympanic Allograft: A Case Report.](https://pubmed.ncbi.nlm.nih.gov/40690305/) (2025 Jul 21) - The Journal of craniofacial surgery
• [Selecting Substitutes for Cranial Dural Repair and Preventing Intracranial Iatrogenic Amyloid Transmission.](https://pubmed.ncbi.nlm.nih.gov/40693052/) (2025 Jun) - Cureus

References

[@selecting]